Heart Drug Trasylol May Boost Risk of Death
Filed in archive Corporate and Industrial News , Drugs, Vaccines and Therapeutics by ruth on October 30, 2007
Bayer said it believes Trasylol remains a safe and effective treatment option, but that the company would work with the FDA and regulators in other countries to re-evaluate the drug's risks and benefits and determine where any label changes are needed.
The FDA said such changes, as well as other, unspecified regulatory actions, may result.
Source: Fox News
Permalink: Heart Drug Trasylol May Boost Risk of Death
Tags:
FDA heart+disease trasylol heart+surgery heart+bypass biotech risk+death drug+trasylol
Trackback: http://www.creative-weblogging.com/cgi-bin/mt-tb.pl/99501







